The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity

被引:25
|
作者
Bojic, Mirza [1 ]
Kondza, Martin [2 ]
Rimac, Hrvoje [1 ]
Benkovic, Goran [3 ]
Males, Zeljan [4 ]
机构
[1] Univ Zagreb, Dept Pharmaceut Chem, Fac Pharm & Biochem, A Kovacica 1, Zagreb 10000, Croatia
[2] Univ Mostar, Fac Pharm, Matice Hrvatske, Mostar 88000, Bosnia & Herceg
[3] Agcy Med Prod & Med Devices, Ksaverska Cesta 4, Zagreb 10000, Croatia
[4] Univ Zagreb, Dept Pharmaceut Bot, Fac Pharm & Biochem, Schrottova 39, Zagreb 10000, Croatia
来源
MOLECULES | 2019年 / 24卷 / 17期
关键词
flavonoids; CYP1A2; CYP2A6; CYP2C8; CYP2D6; inhibition; GINKGO-BILOBA EXTRACT; CYTOCHROME-P450; 3A4; PHARMACOKINETIC INTERACTION; DRUG INTERACTIONS; INHIBITION; METABOLISM; PREDICTION; CLEARANCE; COMMON; MORIN;
D O I
10.3390/molecules24173174
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochromes P450 are major metabolic enzymes involved in the biotransformation of xenobiotics. The majority of xenobiotics are metabolized in the liver, in which the highest levels of cytochromes P450 are expressed. Flavonoids are natural compounds to which humans are exposed through everyday diet. In the previous study, selected flavonoid aglycones showed inhibition of CYP3A4 enzyme. Thus, the objective of this study was to determine if these flavonoids inhibit metabolic activity of CYP1A2, CYP2A6, CYP2C8, and CYP2D6 enzymes. For this purpose, the O-deethylation reaction of phenacetin was used for monitoring CYP1A2 enzyme activity, coumarin 7-hydroxylation for CYP2A6 enzyme activity, 6-alpha-hydroxylation of paclitaxel for CYP2C8 enzyme activity, and dextromethorphan O-demethylation for CYP2D6 enzyme activity. The generated metabolites were monitored by high-performance liquid chromatography coupled with diode array detection. Hesperetin, pinocembrin, chrysin, isorhamnetin, and morin inhibited CYP1A2 activity; apigenin, tangeretin, galangin, and isorhamnetin inhibited CYP2A6 activity; and chrysin, chrysin-dimethylether, and galangin inhibited CYP2C8. None of the analyzed flavonoids showed inhibition of CYP2D6. The flavonoids in this study were mainly reversible inhibitors of CYP1A2 and CYP2A6, while the inhibition of CYP2C8 was of mixed type (reversible and irreversible). The most prominent reversible inhibitor of CYP1A2 was chrysin, and this was confirmed by the docking study.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method
    Mwenifumbo, JC
    Myers, MG
    Wall, TL
    Lin, SK
    Sellers, EM
    Tyndale, RF
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (03): : 189 - 192
  • [32] Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
    Carrillo, JA
    Dahl, ML
    Svensson, JO
    Alm, C
    Rodriguez, I
    Bertilsson, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) : 183 - 190
  • [33] Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity
    Matzke, GR
    Frye, RF
    Early, JJ
    Straka, RJ
    Carson, SW
    PHARMACOTHERAPY, 2000, 20 (02): : 182 - 190
  • [34] Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations
    Kim, Jeong-Hyun
    Cheong, Hyun Sub
    Park, Byung Lae
    Kim, Lyoung Hyo
    Shin, Hee Jung
    Na, Han Sung
    Chung, Myeon Woo
    Shin, Hyoung Doo
    ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (01) : 115 - 128
  • [35] Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations
    Jeong-Hyun Kim
    Hyun Sub Cheong
    Byung Lae Park
    Lyoung Hyo Kim
    Hee Jung Shin
    Han Sung Na
    Myeon Woo Chung
    Hyoung Doo Shin
    Archives of Pharmacal Research, 2015, 38 : 115 - 128
  • [36] STUDIES OF IN VITRO MODULATORY EFFECT OF LABISIA PUMILA ON CYP1A2, CYP2A6 AND CYP3A4
    Ong, Chin Eng
    Pan, Yan
    Abd-Rashid, Badrul Amini
    Ismail, Zakiah
    Ismail, Rusli
    Mak, Joon Wah
    DRUG METABOLISM REVIEWS, 2014, 45 : 82 - 82
  • [37] Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity
    Fukami, T
    Nakajima, M
    Higashi, E
    Yamanaka, H
    Sakai, H
    McLeod, HL
    Yokoi, T
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1202 - 1210
  • [38] Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
    Jeppesen, U
    Gram, LF
    Vistisen, K
    Loft, S
    Poulsen, HE
    Brosen, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) : 73 - 78
  • [39] Genetic polymorphism of drug metabolizing enzymes:: New mutations in CYP2D6 and CYP2A6 genes in Japanese
    Yokoi, T
    Kamataki, T
    PHARMACEUTICAL RESEARCH, 1998, 15 (04) : 517 - 524
  • [40] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
    Ariyoshi, N
    Takahashi, Y
    Miyamoto, M
    Umetsu, Y
    Daigo, S
    Tateishi, T
    Kobayashi, S
    Mizorogi, Y
    Loriot, MA
    Stücker, I
    Beaune, P
    Kinoshita, M
    Kamataki, T
    PHARMACOGENETICS, 2000, 10 (08): : 687 - 693